Woodlands, Texas-based precision drug development company MolecularHealth has named Stephen Jones, Thomas Kean, and Kathleen Lokay to its advisory board.
The three new members, with combined decades of experience in oncology and patient support, will join eight other members of the board, which the company has been steadily adding to over the past six months.
“I speak for the whole executive team when I say that we are honored to welcome Dr. Jones, Mr. Kean and Ms. Lokay to the advisory board. Each new member boasts admirable careers in the fields of cancer research, prevention and patient support. Their combined experiences and knowledge will be an indispensable resource to MolecularHealth as we continuously work to improve our offering,” said Lloyd Everson, M.D., CEO of MolecularHealth.
The new board member, Stephen Jones, has been involved in the development of 17 new drugs or combination studies that have already been approved by the FDA for cancer treatment. During his more than forty years of biotech experience, Jones served as breast cancer research chair and emeritus partner at Texas Oncology for the last fifteen years. From 1999 to 2014, he also served as the medical director of research at U.S. Oncology Research.
For Jones, the key point in the sector of the industry that MolecularHealth seeks to serve is that “there are a number of companies out there that can run lab tests and provide reports back to physicians, but the reality is many of those reports are unhelpful. Physicians are looking for the bottom line: ‘How is this information going to help my patient?’”
For the other new MolecularHealth board member, Thomas Kean, “what the industry needs is a timely way to deliver physicians the right information that will help them and their patients make good clinical decisions with positive and effective outcomes.” According to Kean, “with the ability to map the genome, we’re creating tons of new information at an exponential rate. However, the challenge of the genomic revolution is how to synthesize this information and put it together in an actionable way. MolecularHealth has created a promising approach for making that happen in a timely and accurate fashion”. With thirty-five years of experience in public health, Kean has worked to prevent and control chronic disease at the University of Texas.
Community side of oncology
The third new member of the board, Kathleen Lokay, explained that “one of MolecularHealth’s strategies is to work more on the community side of oncology, where I see a gap in the market right now.” Lokay envisions MolecularHealth’s offerings as perfect match for delivering patient-centric diagnostic and treatment services that complement this ethic.
Lokay, a certified public accountant with a BBA in accounting from the University of Texas at Austin, had worked with the affiliate company of the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh Cancer Institute since 2008, to assist oncologists with ensuring value-based care. Her goal is to improve the quality and efficiency of cancer care.
At the same time, the company is ready to launch its cancer treatment decision support platform, the TreatmentMAP, which new advisory board member Stephen Jones believes will develop and deliver the bottom line in the industry better than “anybody else,” due to its innovative bioinformatics and computing capabilities.